I get that, on the other side of it there's,
Post# of 30028
(Total Views: 387)
Posted On: 03/09/2022 11:10:03 AM
I get that, on the other side of it there's,
They can afford it because business and revenue is strong enough to support the team.
They need a team that big to handle the amount of business and they would be losing business if they dihave enough people.
The team assembled is built to splinter off to create 3CL Sciences
"...As we await the completion of the formation of 3CL Pharma together with NLC Pharma"
And as for Mr. Meiselbach, yup here's been around and now promoted. Not as Pres of GA but as VP of Gov't Affairs, sobhe either earned it or they just need a warm body.
I'm going with he earned it.
I specifically liked this from his Bio...
Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years. In his role, he managed BIO’s international government affairs portfolio for Asia Pacific and worked with BIO’s members to craft international engagement strategies to promote member companies’ business interests abroad. Prior to this, while based out of Singapore, Mr. Meiselbach built and managed the Asia Pacific portfolio of Frontier Strategy Group’s Expert Advisory Network, a broad network of in-market experts, professionals, and former officials who supported Frontier Strategy Group’s clients’ expansion into emerging markets.
So, yes there's always concert with a bloated team, but there could be reason the team is also not big enough, hence all the hiring.
We'll know more once the ink has dried and NLC Sciences is a full entity spun off from Todos which is the plan.
3CL Sciences will be spun off to sell, partner or exist as a stand alone from Todos in order for Todos to focus on its core business Videssa which seems to be gaining traction. The plan is for it to be spun out so Todos won't be the one funding it.
Per Gerald's Tweet yesterday on his interview.
"Topic switched to Videssa! Videssa starting to get attention now that people understand Grail’s test is being used to screen for breast cancer with poor sensitivity. Videssa solves this problem. TBIA could deliver on Grail’s promise re: all cancer screen. Videssa is game-changer"
https://twitter.com/G_Commish/status/15013012...g&s=19
Another reason I like the VP spot for Mr. Meiselbach.
"Mr. Meiselbach will focus on liaising with governments regarding the deployment of Tollovir™, Tollovid® and Videssa®"
https://investor.todosmedical.com/news-events...esident-of
Lots to be worried or concerned about, but lots to be excited about as well.
Time will tell.
They can afford it because business and revenue is strong enough to support the team.
They need a team that big to handle the amount of business and they would be losing business if they dihave enough people.
The team assembled is built to splinter off to create 3CL Sciences
"...As we await the completion of the formation of 3CL Pharma together with NLC Pharma"
And as for Mr. Meiselbach, yup here's been around and now promoted. Not as Pres of GA but as VP of Gov't Affairs, sobhe either earned it or they just need a warm body.
I'm going with he earned it.
I specifically liked this from his Bio...
Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years. In his role, he managed BIO’s international government affairs portfolio for Asia Pacific and worked with BIO’s members to craft international engagement strategies to promote member companies’ business interests abroad. Prior to this, while based out of Singapore, Mr. Meiselbach built and managed the Asia Pacific portfolio of Frontier Strategy Group’s Expert Advisory Network, a broad network of in-market experts, professionals, and former officials who supported Frontier Strategy Group’s clients’ expansion into emerging markets.
So, yes there's always concert with a bloated team, but there could be reason the team is also not big enough, hence all the hiring.
We'll know more once the ink has dried and NLC Sciences is a full entity spun off from Todos which is the plan.
3CL Sciences will be spun off to sell, partner or exist as a stand alone from Todos in order for Todos to focus on its core business Videssa which seems to be gaining traction. The plan is for it to be spun out so Todos won't be the one funding it.
Per Gerald's Tweet yesterday on his interview.
"Topic switched to Videssa! Videssa starting to get attention now that people understand Grail’s test is being used to screen for breast cancer with poor sensitivity. Videssa solves this problem. TBIA could deliver on Grail’s promise re: all cancer screen. Videssa is game-changer"
https://twitter.com/G_Commish/status/15013012...g&s=19
Another reason I like the VP spot for Mr. Meiselbach.
"Mr. Meiselbach will focus on liaising with governments regarding the deployment of Tollovir™, Tollovid® and Videssa®"
https://investor.todosmedical.com/news-events...esident-of
Lots to be worried or concerned about, but lots to be excited about as well.
Time will tell.
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼